Sign up for the Packaging Digest News & Insights newsletter.
Catalent Pharma Solutions teams with Endotis Pharma
Lauren R. Hartman
November 12, 2015
1 Min Read
Catalent Pharma Solutions, a leading provider of advanced oral drug-delivery technologies to the pharmaceutical industry, has entered into a strategic alliance with Endotis pharma for the development of oral formulations of synthetic oligosaccharides.
Using Catalent's drug-delivery technologies, the two companies will team exclusively to develop certain oral formulations of small-glycol drugs. Oral formulations of synthetic oligosaccharides will allow full exploitation of the therapeutic potential of small-glycol drugs, which to date are administered only intravenously or subcutaneously.
Catalent and Endotis are initially focusing on the preclinial development of Endotis' EP37151 compound. EP37151 is a first-in-class oral synthetic oligosaccharide anticoagulant which, as an indirect factor Xa inhibitor, acts via antithrombin activation. The companies expect to initiate a Phase 1 clinical trial program during hte second quarter of 2010, and hope to have more oral anticoagulants enter development within the next year.
"This collaboration with Endotis, based upon a unique combination of complementary expertise, has been providing exciting results, providing that the various technical hurdles associated with the oral delivery of small-glycol drugs can be overcome," says Tom Stuart, group president of Catalent's Oralt Technologies segment.
Source: Catalent Pharma Solutions
You May Also Like
What Role Does ESD-Safe Packaging Serve?Mar 1, 2024|5 Min Read
Kellogg’s Pushes Sustainable Packaging from Good to Gr-r-reat!Feb 29, 2024|3 Min Read
Healthcare Packaging News and Top IssuesFeb 29, 2024|4 Min Read
Best in New Food and Beverage PackagingFeb 28, 2024|3 Min Read